Psychometric Analysis of the Heart Failure Somatic Perception Scale as a Measure of XXXX Symptom Perception.

@entity1 @entity296 @entity712 @entity1353
BACKGROUND: Symptoms are known to predict survival among @entity1 with @entity712 ( @entity712 ), but discrepancies exist between @entity1 ' and health providers' perceptions of @entity712 symptom burden. OBJECTIVE: The purpose of this study is to quantify the internal consistency, validity, and prognostic value of @entity1 perception of a broad range of @entity712 symptoms using an @entity712 -specific physical symptom measure, the 18-item @entity712 Somatic Perception Scale v. 3. METHODS: Factor analysis of the @entity712 Somatic Perception Scale was conducted in a convenience sample of 378 @entity1 with chronic @entity712 . Convergent validity was examined using the Physical Limitation subscale of the Kansas @entity296 Questionnaire. Divergent validity was examined using the Self-care of @entity712 Index self-care management score. One-year survival based on @entity712 Somatic Perception Scale scores was quantified using Cox regression controlling for Seattle @entity712 Model scores to account for clinical status, therapeutics, and lab values. RESULTS: The sample was 63% male, 85% white, 67% functionally compromised (New York Heart Association class III-IV) with a mean (SD) age of 63 (12.8) years. Internal consistency of the @entity712 Somatic Perception Scale was a = .90. Convergent (r = -0.54, P < .0001) and divergent (r = 0.18, P > .05) validities were supported. Controlling for Seattle @entity712 scores, @entity712 Somatic Perception Scale was a significant predictor of 1-year survival, with those most symptomatic having worse survival (hazard ratio, 1.012; 95% confidence interval, 1.001-1.024; P = .038). CONCLUSIONS: Perception of @entity712 symptom burden as measured by the @entity712 Somatic Perception Scale is a significant predictor of survival, contributing additional prognostic value over and above objective Seattle @entity712 Risk Model scores. This analysis suggests that assessment of a broad range of @entity712 symptoms, or those related to @entity1353 or early and subtle symptoms, may be useful in evaluating therapeutic outcomes and predicting event-free survival.
